Integra: 3 Key Takeaways for Long-Term Investors

Integra reduced its full-year 2026 revenue guidance by $30 million due to severe Cincinnati plant flooding and slower tissue reconstruction business recovery. Despite near-term supply disruptions, the company demonstrated underlying resilience with record operating cash flow of $96 million and strong neurosurgery segment growth of 6.5% organically. Manufacturing capabilities are expected to resume in Q2 2027, with management prioritizing commercial execution and debt reduction.